Hemogenyx Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Hemogenyx Pharmaceuticals has a total shareholder equity of £3.0M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £6.1M and £3.1M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£1.64m |
| Equity | UK£3.02m |
| Total liabilities | UK£3.09m |
| Total assets | UK£6.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 5HU's short term assets (£2.5M) exceed its short term liabilities (£564.3K).
Long Term Liabilities: 5HU's short term assets (£2.5M) do not cover its long term liabilities (£2.5M).
Debt to Equity History and Analysis
Debt Level: 5HU is debt free.
Reducing Debt: 5HU has no debt compared to 5 years ago when its debt to equity ratio was 415.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 5HU has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 5HU is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.